S&P Futures
3,771.75 -49.50 (-1.30%) Dow Futures
30,680.00 -319.00 (-1.03%) Nasdaq Futures
11,497.75 -193.25 (-1.65%) Russell 2000 Futures
1,696.90 -24.50 (-1.42%) Crude Oil
109.57 -0.21 (-0.19%) Gold
1,812.40 -5.10 (-0.28%)
Silk Road Medical, Inc (SILK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 37.52 |
| Open | 37.40 |
| Bid | 37.30 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 36.44 - 37.96 |
| 52 Week Range | 27.21 - 67.49 |
| Volume | |
| Avg. Volume | 367,514 |
| Market Cap | 1.317B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SILK
Related Research
- Silk Road Medical, Inc.Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called Transcarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device is deployed to temporarily reverse blood flow to the brain in order to prevent any broken off clots from moving to the brain.RatingFair ValueEconomic Moat3 months agoArgus Research
- GlobeNewswire
Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR
SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market study, called ROADSTER 3, will fulfill the U.S. Food and Drug Administration’s (FDA) condition of approval for the recent expansion of labeling for the ENROUTE® Transca
- Simply Wall St.
Despite recent gains, Silk Road Medical, Inc (NASDAQ:SILK) insiders are still down US$8.9k after purchasing last year
Insiders who bought US$103k worth of Silk Road Medical, Inc ( NASDAQ:SILK ) stock in the last year have seen some of...
- GlobeNewswire
Silk Road Medical Announces Expanded Medicare Coverage for TCAR in Standard Surgical Risk Patients
SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI’s TCAR Surveillance Pr
